Patents by Inventor Olivier DeBacker

Olivier DeBacker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated nucleic acid molecules which encode GAGE genes and uses thereof
    Patent number: 6939707
    Abstract: The invention relates to nucleic acid molecules which encode members of the GAGE family of tumor rejection antigen precursors and their use.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: September 6, 2005
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Benoit Van den Eynde, Olivier DeBacker, Thierry Boon-Falleur
  • Isolated nucleic acid molecules which encode GAGE genes and uses thereof
    Publication number: 20020127613
    Abstract: Peptides which bind to HLA-A29 molecules are disclosed. These molecules satisfy motifs defined by SEQ ID NO: 23, SEQ ID NO: 24 or SEQ ID NO: 25. Also described are minigenes which encode the peptides of the invention as well as their use.
    Type: Application
    Filed: February 13, 2001
    Publication date: September 12, 2002
    Inventors: Pierre van der Bruggen, Benoit van den Eynde, Olivier DeBacker, Thierry Boon-Falleur
  • Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
    Patent number: 6069001
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described. Tumor rejection antigens are also shown.
    Type: Grant
    Filed: February 15, 1996
    Date of Patent: May 30, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Benoit Van den Eynde, Olivier DeBacker, Thierry Boon-Falleur
  • Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
    Patent number: 6013481
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described. Tumor rejection antigens are also shown.
    Type: Grant
    Filed: June 24, 1996
    Date of Patent: January 11, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Olivier DeBacker, Benoit van den Eynde, Thierry Boon-Falleur
  • Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
    Patent number: 5858689
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described. Tumor rejection antigens are also shown.
    Type: Grant
    Filed: September 21, 1995
    Date of Patent: January 12, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Benoit van den Eynde, Olivier DeBacker, Thierry Boon-Falleur
  • Isolated peptides derived from tumor rejection antigens, and their use
    Patent number: 5648226
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described. Tumor rejection antigens are also shown.
    Type: Grant
    Filed: January 10, 1995
    Date of Patent: July 15, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Benoit Van den Eynde, Olivier DeBacker, Thierry Boon-Falleur